therapeutics

Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases Agilent…

Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics outlined its upcoming priorities and near-term milestones that…

Senior Connect Acquisition  a publicly traded special purpose acquisition company, has announced that it has entered into a non-binding letter of…

TandemAI announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer. Dr. Swann joins TandemAI with…

The BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research,…

– New research partnerships with world-leading institutions University of Bern, University Hospital of Bern and Lausanne University Hospital – – …

Xbiome expects to commence Phase 1b trial of next-generation oral live biotherapeutic product program M201 in 2022 Adds a third clinical-stage…

Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the…

– JIXING to lead development and commercialization of LNZ100 and LNZ101 in Greater China – – LENZ to receive up to $110 million in upfront and…

MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics STING is a…